New utility of an old marker: Serial α-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy

Journal of Clinical Oncology

Volumn 27, Issue 3, 2009, Pages 446-452

  Chan, Stephen L ^a   Mo, Frankie K F ^a   Johnson, Philip J ^a   Hui, Edwin P ^a   Ma, Brigette B Y ^a   Ho, Wingm ^a   Lam, Kwok C ^a   Chan, Anthony T C ^a   Mok, Tony S K ^a   Yeo, Winnie ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ALPHA2B INTERFERON; CISPLATIN; DOXORUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; SEROLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 58749090909     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.8151     Document Type: Article

References (31)

1. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80:827-841, 1999
2. McGlynn KA, Tarone RE, El-Serag HB: Acom- parison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 15:1198-1203, 2006
3. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogene- sis. Gastroenterology 132:2557-2576, 2007
4. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 362:1907-1917, 2003
5. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750, 1999
6. WHO: WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48. Geneva, Switzerland, WHO, 1979
7. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
8. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
9. Johnson PJ: Hepatocellular carcinoma: Is current therapy really altering outcome? Gut 51:459-462, 2002
10. Johnson PJ: The role of serum alpha- fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 5:145-159, 2001
11. Leung TW, Patt YZ, Lau WY, et al: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676-1681, 1999
12. Lau WY, Leung TW, Lai BS, etal: Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 233:236-241, 2001
13. Barone RM, Byfield JE, Goldfarb PB, et al: Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases. Cancer 50:850-862, 1982
14. Bruix J, Sherman M, Llovet JM, et al: Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference-European Association for the Study of the Liver. J Hepatol 35:421-430, 2001
15. Nomura F, Ohnishi K, Tanabe Y: Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels: Analysis of 606 patients. Cancer 64:1700-1707, 1989
16. Lok AS, Lai CL: Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellu-lar carcinoma. Hepatology 9:110-115, 1989
17. The Cancer of the Liver Italian Program (CLIP) Investigators: A new prognostic system for hepato- cellular carcinoma: A retrospective study of 435 patients. Hepatology 28:751-755, 1998
18. Leung TW, Tang AM, Zee B, et al: Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients. Cancer 94:1760-1769, 2002
19. Chevret S, Trinchet JC, Mathieu D, et al: A new prognostic classification for predicting survival in patients with hepatocellular carcinoma: Groupe d'Etude et de Traitement du Carcinome Hepatocellular. J Hepatol 31:133-141, 1999
20. 20.Johnson PJ, Williams R: Serum alpha-fetoprotein estimations and doubling time in hepa- tocellular carcinoma: Influence of therapy and possible value in early detection. J Natl Cancer Inst 64:1329-1332, 1980
21. Mclntire KR, Vogel CL, Princler GL, et al: Serum alpha-fetoprotein as a biochemical marker for hepatocellular carcinoma. Cancer Res 32:1941-1946, 1972
22. Yeo W, Mok TS, Zee B, et al: A randomized phase III study of doxorubicin versus cisplatin/inter- feron alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532-1538, 2005
23. Freemantle N: Interpreting the results of secondary end points and subgroup analyses in clinical trials: Should we lock the crazy aunt in the attic? BMJ 322:989-991, 2001
24. Assmann SF, Pocock SJ, Enos LE, et al: Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355:1064-1069, 2000
25. Yusuf S, Wittes J, Probstfield J, et al: Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 266: 93-98, 1991
26. Pocock SJ, Hughes MD, Lee RJ: Statistical prob ems in the reporting of c inica tria s: A survey of three medical journals. N Engl J Med 317:426-432, 1987
27. McIntire KR, Vogel CL, Primack A, et al: Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer 37:677-683, 1976
28. Johnson PJ: Critical issues in the design and implementation of clinical trials in hepatocellular carcinoma. Expert Rev Anticancer Ther 3:421-423, 2003
29. Llovet JM, Ricci S, Mazzaferro V, et al: Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC. J Clin Oncol 25:1s, 2007 (suppl; abstr LBA1)
30. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006
31. Abou-Alfa GK, Johnson PJ, Knox JJ, et al: Preliminary results from a phase II randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Eur J Cancer Suppl 5:259, 2007 (abstr 3500)